NIBEC said on the 7th that it will attend the JP Morgan Healthcare Conference in San Francisco and hold partnering meetings with global pharmaceutical and biotech corporations for technology transfer and joint development.
At this JP Morgan Healthcare Conference, NIBEC will continue talks with global partners focusing on its regenerative peptide-based platform and key research achievements. Based on preclinical results and central nervous system (CNS) research findings recently unveiled on the international academic stage, it plans to discuss expanding indications and subsequent technology transfers.
NIBEC recently presented a poster on preclinical trial results for the obesity treatment candidate "Regonotide" at an international peptide society meeting, disclosing efficacy data on weight control and metabolism. The study centered on the efficacy and mechanism of action of the peptide-based drug candidate.
It also presented regenerative peptide research results targeting central nervous system disorders at an international CNS society meeting, introducing both the expansion of its research scope into brain diseases and the potential to extend its technology. NIBEC noted that, based on these results, it is concurrently pursuing talks on joint research and technology transfer in the CNS field.
In addition, regarding the pulmonary fibrosis therapy it transferred in May last year, NIBEC plans to discuss development strategy and clinical design with the counterpart company during the JP Morgan Healthcare Conference period ahead of entry into phase 2. This is part of follow-up consultations for stepwise development after the existing technology transfer agreement.
Furthermore, it plans to continue global partnering meetings on a new peptide candidate targeting renal fibrosis. The candidate is a peptide developed on a regenerative mechanism different from existing approaches.
A company official said, "Renal fibrosis, due to the nature of the disease, makes it difficult to prove clinical efficacy, and many pipelines have adjusted strategies or switched indications during development," adding, "In light of these limitations, we will present a candidate with a new mechanism approached from a tissue regeneration perspective."
The official added, "The JP Morgan Healthcare Conference is a venue to directly explain and discuss the research results already disclosed and the post-transfer development stage," saying, "We will conduct meetings centered on concrete joint development and technology transfer discussions."